About Sengenics
Sengenics is a company based in Singapore (Singapore) founded in 2008 was acquired by Summa Equity in October 2020. Sengenics offers products and services including i-Ome Cancer, i-Ome Discovery, and Autoantibody Profiling. Sengenics operates in a competitive market with competitors including Inflammatix, Agendia, GenomeDx Biosciences, Affymetrix and Akonni, among others.
- Headquarter Singapore, Singapore
- SectorsHealthcare
- Email••••••••
- Website sengenics.com
- Social LinkedIn X Facebook
- Acquired by Summa Equity (Oct 2020)
- Legal Name Sengenics Corporation Llc
- InvestorsThe Michael J. Fox Foundation
& 1 more
- Acquired bySumma Equity
(Oct 14, 2020)
Products & Services of Sengenics
Sengenics offers a comprehensive portfolio of products and services, including i-Ome Cancer, i-Ome Discovery, and Autoantibody Profiling.
Tool for profiling autoantibodies in cancer research and biomarker detection
System for autoantibody analysis across various diseases and isotypes
Service for discovering and validating biomarkers in clinical research
Funding Insights of Sengenics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Sengenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| 15 Dec 2020 | – | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Sengenics
Sengenics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include The Michael J. Fox Foundation and Summa Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Summa Equity is focused on thematic and impact investments. | 2016 | summaequity.com | - | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Sengenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sengenics
7 people are tracked at Sengenics (1 in leadership, 4 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Zafirah Azween | Deputy Head of Protein Production | Leadership |
Arif Anwar | Board Member | Board & advisors |
Nicolas H. Roelofs | Chair | Board & advisors |
Yvonne Linney | Board Member | Board & advisors |
Christoph Waer | Board Member | Board & advisors |
Dayle Blencowe | Consultant (Technical Operations) | Team |
S.M.Sajjad Ghillani | Technical Support Officer | Team |
Complete people profiles for Sengenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sengenics
3 dated milestones of Sengenics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Sengenics is founded.
- Exit Acquired by Summa Equity.
- Funding First funding round.
Competitors of Sengenics
Sengenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, GenomeDx Biosciences, Affymetrix and Akonni, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.5M | 54 | Provider of diagnostic solutions for systemic infections | |
| agendia.com | 2003 | Irvine, United States | $123.0M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| genomedx.com | 2008 | San Diego, United States | $69.7M | 159 | Genomic tests for urologic cancers are developed and commercialized. | |
| affymetrix.com | 1991 | Santa Clara, United States | – | 721 | Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level | |
| akonni.com | 2003 | Frederick, United States | $39.7M | 12 | Molecular diagnostics for complex infections are developed by Akonni. | |
| kromatid.com | 2007 | Fort Collins, United States | $14.5M | – | Molecular and genetic tests for detecting disease-causing mutations are provided. | |
| indevr.com | 2003 | Boulder, United States | $16.0M | – | Biotherapeutics, vaccines, and diagnostic products are manufactured and developed. | |
| pamgene.com | 1999 | Virginia, United States | $17.9M | – | PamGene is focused on kinome-based biomarkers for drug development and therapy. | |
| synplogen.com | 2017 | Tsuruoka, Japan | – | – | DNA synthesis technology is developed using microbial methods. | |
| exiqon.com | 1995 | Vedbaek, Denmark | $22.9M | 65 | LNA-based tools are developed for diagnostics and research applications. |
Detailed competitors of Sengenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sengenics
Complete news archive for Sengenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sengenics
10 companies that operate in the same segment as Sengenics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sengenics
Sengenics was founded in 2008 and raised its 1st funding round 12 years after it was founded.
Sengenics is headquartered in Singapore, Singapore.
Sengenics is a genomics and proteomics based diagnostics and research company. Sengenics flagship product is their patented Immunome autoantibody profiling protein array for use in immunology or cancer research. The Immunome platform was jointly developed by Cambridge and Oxford Universities and is the only protein array platform where all proteins are correctly folded. Apart from their proteomics product, the company offers genomics-based diagnostics services from its CLIA and CAP certified labs using NGS and microarray technologies. The company offers postnatal diagnostics, cardiac and cancer risk tests, and developmental delay diagnostics, along with Sequenoms NIPT - MaterniT21 and VisibiliT tests. The NIPT tests are carried out at Sequenoms CLIA and CAP accredited laboratory. Along with their clinical tests, the company also offers research services to clients in biomarker discovery, NGS, and Bioinformatics.
Sengenics's top competitors include Inflammatix, Agendia and KromaTiD.
Sengenics offers i-Ome Cancer, i-Ome Discovery, and Autoantibody Profiling.
Sengenics has 2 investors. Key investors include The Michael J. Fox Foundation, and Summa Equity.
Sengenics operates through Sengenics Corporation Llc.
Yes. Sengenics was acquired by Summa Equity in October 2020.